Our Platform
Logic-Gated Multispecifics
Sovran Bio's technology is built on deep team experience in drugging tumor-associated antigens and other well validated therapeutic targets. We engineer therapeutic candidates that exploit novel combinations of known disease markers while sparing healthy tissue.
Novel ADCs
Our ADC programs leverage clinically validated linker-payloads along with novel payload combinations to drive optimal patient responses.
Triple Mechanism of Action
By combining multiple mechanisms of action in a single molecule, we achieve synergistic effects that monospecific approaches cannot replicate — improving efficacy while reducing resistance and toxicity.
Pan-Tumor Applicability
Our lead program is designed for broad utility across tumor types, enabling a pipeline strategy that maximizes the impact of our core platform technology.
